Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

This registry study compares two treatment strategies in people who developed relapsing-remitting multiple sclerosis (MS) after age 50: starting with a moderate-strength MS drug and escalating if needed, versus starting immediately with a high-strength drug. It aims to find the better approach for older adults newly diagnosed with MS. **You may be eligible if...** - Your first MS symptoms appeared after age 50 - You started MS treatment within 2 years of your first symptoms - You are currently on or have been treated with either moderate-strength MS drugs (such as teriflunomide, dimethyl fumarate, glatiramer acetate, interferon beta) or high-potency drugs (such as natalizumab, ocrelizumab, cladribine, fingolimod) **You may NOT be eligible if...** - You have primary or secondary progressive MS (not relapsing-remitting) - Your first MS episode occurred before age 50 Talk to your doctor to see if this trial is right for you.